Contrasting of XBiotech Inc. (XBIT) and Arcturus Therapeutics Ltd. (NASDAQ:ARCT)

Both XBiotech Inc. (NASDAQ:XBIT) and Arcturus Therapeutics Ltd. (NASDAQ:ARCT) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XBiotech Inc. N/A 0.00 22.28M -0.65 0.00
Arcturus Therapeutics Ltd. 10.20M 5.20 26.05M -4.19 0.00

Demonstrates XBiotech Inc. and Arcturus Therapeutics Ltd. earnings per share, gross revenue and valuation.


Table 2 shows XBiotech Inc. and Arcturus Therapeutics Ltd.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
XBiotech Inc. 0.00% -41.4% -39.5%
Arcturus Therapeutics Ltd. -255.39% 0% 0%

Volatility & Risk

XBiotech Inc. has a 0.31 beta, while its volatility is 69.00%, thus making it less volatile than Standard and Poor’s 500. In other hand, Arcturus Therapeutics Ltd. has beta of 2.09 which is 109.00% more volatile than Standard and Poor’s 500.


XBiotech Inc.’s Current Ratio and Quick Ratio are 9.3 and 9.3 respectively. The Current Ratio and Quick Ratio of its competitor Arcturus Therapeutics Ltd. are 2.5 and 2.5 respectively. XBiotech Inc. therefore has a better chance of paying off short and long-term obligations compared to Arcturus Therapeutics Ltd.

Insider and Institutional Ownership

Roughly 13.2% of XBiotech Inc. shares are owned by institutional investors while 14.6% of Arcturus Therapeutics Ltd. are owned by institutional investors. Insiders owned 37.5% of XBiotech Inc. shares. Competitively, insiders own roughly 23.9% of Arcturus Therapeutics Ltd.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XBiotech Inc. 13.76% 40.3% 121% 137.44% 90.53% 82.28%
Arcturus Therapeutics Ltd. 3.88% 1.8% -16.69% -36.69% -7.96% 12.36%

For the past year XBiotech Inc.’s stock price has bigger growth than Arcturus Therapeutics Ltd.


XBiotech Inc. beats on 5 of the 9 factors Arcturus Therapeutics Ltd.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.